Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

SML2871

Sigma-Aldrich

Udenafil

≥98% (HPLC)

Synonyma:

3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide, 3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide, 3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide, 5-[2-Propoxy-5-(1-methyl-2-pyrrolidinylethyl amidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one, 5-[2-Propyloxy-5-(1-methyl-2-pyrrolidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one, DA 8159, DA-8159, DA8159

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C25H36N6O4S
Číslo CAS:
Molekulová hmotnost:
516.66
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[S](=O)(=O)(NCCC4N(CCC4)C)c1cc(c(cc1)OCCC)c2[nH][c](c3[n](nc(c3n2)CCC)C)=O

InChI

1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)

InChI key

IYFNEFQTYQPVOC-UHFFFAOYSA-N

Biochem/physiol Actions

Udenafil (DA-8159) is an orally active, cGMP-competitive, potent and selective phosphodiesterase type 5 (PDE5) inhibitor (cellular PDE5 activity IC50 = 5.84/8.25 nM in rabbit/human platelets; IC50 = 53.3 nM/PDE6, 870 nM/PDE1, 52 μM/PDE3,101 μM/PDE2). Udenafil shows in vivo therapeutic efficacy in a rat model of monocrotaline-induced pulmonary hypertension (1 or 5 mg/kg bid po.) and induces penile erection in experimental animals in vivo (0.3-10 mg/kg po. in rabbits & rats).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3


Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Seong Yul Ryu et al.
The world journal of men's health, 36(1), 41-49 (2017-11-23)
High-fat (HF) feeding induces hypothalamic leptin resistance via the activation of toll-like receptor 4 (TLR4). TLR4 deficiency confers resistance to diet-induced obesity. Udenafil, an anti-impotence drug, inhibits TLR4 in airway epithelial cells in vitro. In this study, we evaluated whether
T Y Oh et al.
Archives of pharmacal research, 23(5), 471-476 (2000-11-04)
DA-8159, a new phosphodiesterase 5 inhibitor, was assessed for its erectogenic potential by a penile erection test in rats, the relaxation of isolated rabbit corpus cavernosum (CC), and estimation of the intracavernous pressure (ICP) in the anesthetized dog. Oral administration
Anne Marie Dupuy et al.
Clinical chemistry and laboratory medicine, 56(3), 413-421 (2017-09-10)
Blood specimens are transported from clinical departments to the biochemistry laboratory by hospital courier service, sometimes over long distances. The aim of this study was to assess the stability of common biochemical analytes in venous blood under our routine transport
Kyung Koo Kang et al.
Archives of pharmacal research, 26(8), 612-619 (2003-09-12)
In this study, we evaluated the effects of oral administration of DA-8159, a selective phosphodiesterase-5 inhibitor, on the development of pulmonary hypertension (PH) induced by monocrotaline (MCT). Rats were administered either MCT (60 mg/kg) or saline. MCT-treated rats were divided
H J Shim et al.
Biopharmaceutics & drug disposition, 22(3), 109-117 (2001-12-18)
The subacute toxicities and toxicokinetics of a new erectogenic, DA-8159, were evaluated after single (at the 1st day) and 4-week (at the 28th day) oral administration of the drug, in doses of 0 (to serve as a control), 12.5, 50

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.